A. Stopeck

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases

W. Jeffrey Allard, Jeri Matera, Michael Craig Miller et al. · Journal of Clinical Oncology · 2004 · 164 citations

Healthy Subjects, Oncologic Imaging, Blood Cell +20

Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

Shanu Modi, S. Sugarman, A. Stopeck et al. · Journal of Clinical Oncology · 2008 · 62 citations

Breast Oncology, Immunology, Hsp90 Inhibitor Tanespimycin +22

Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin’s lymphoma (NHL): Southwest Oncology Group Study S0108

A. Stopeck, William Bellamy, Joseph M. Unger et al. · Journal of Clinical Oncology · 2005 · 39 citations

Aggressive Nhl Specimens, Immunology, Pathology +16

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases

W. Jeffrey Allard, Jeri Matera, Michael Craig Miller et al. · Journal of Clinical Oncology · 2004 · 38 citations

Healthy Subjects, Oncologic Imaging, Blood Cell +20

A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC)

Hope S. Rugo, Sandra Franco, P.N. Munster et al. · Journal of Clinical Oncology · 2008 · 19 citations

Breast Oncology, Cardiovascular Pharmacology, Pathology +18